SCHEMBL145290

SCHEMBL145290

COC(=O)c1cc(-c2cccc(Cl)c2)nc2c1[nH]c1ccc(CN3CCOCC3)cc12

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.81
PDE4B Q07343 1/20 0.47
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
PRKD3 O94806 1/20 0.46
KMT2A Q03164 1/20 0.46
PRKD1 Q15139 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PRKD2 Q9BZL6 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CHEK1 O14757 1/20 0.44
CDK7 P50613 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PARP1 P09874 2/20 0.43
MAPK1 P28482 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148206 0.94 JAK2 (0.71) JAK2PDE4BALDH1A1HPGDMEN1
SCHEMBL139499 0.90 JAK2 (1.00) JAK2PARP1
SCHEMBL140303 0.83 JAK2 (0.88) JAK2PARP1
SCHEMBL141027 0.83 JAK2 (0.83) JAK2
SCHEMBL144397 0.82 JAK2 (0.54) JAK2SMN1; SMN2CHEK1CDK7KDM4E
SCHEMBL15800343 0.80 JAK2 (0.71) JAK2PARP1
SCHEMBL140637 0.79 JAK2 (0.88) JAK2PARP1
SCHEMBL143749 0.79 JAK2 (0.51) JAK2MAPK1
SCHEMBL141803 0.75 JAK2 (0.53) JAK2ALDH1A1SMN1; SMN2CHEK1CDK7
SCHEMBL141085 0.74 JAK2 (0.53) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885PDE4B 1504/4885ALDH1A1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.